NUVL vs. ONC, TEVA, BGNE, SMMT, ITCI, VTRS, GMAB, MRNA, RDY, and SRPT
Should you be buying Nuvalent stock or one of its competitors? The main competitors of Nuvalent include Beigene (ONC), Teva Pharmaceutical Industries (TEVA), BeiGene (BGNE), Summit Therapeutics (SMMT), Intra-Cellular Therapies (ITCI), Viatris (VTRS), Genmab A/S (GMAB), Moderna (MRNA), Dr. Reddy's Laboratories (RDY), and Sarepta Therapeutics (SRPT). These companies are all part of the "pharmaceutical products" industry.
Nuvalent vs.
Nuvalent (NASDAQ:NUVL) and Beigene (NASDAQ:ONC) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their community ranking, risk, valuation, profitability, media sentiment, analyst recommendations, earnings, institutional ownership and dividends.
Nuvalent has higher earnings, but lower revenue than Beigene. Beigene is trading at a lower price-to-earnings ratio than Nuvalent, indicating that it is currently the more affordable of the two stocks.
In the previous week, Nuvalent and Nuvalent both had 3 articles in the media. Nuvalent's average media sentiment score of 1.05 beat Beigene's score of 0.77 indicating that Nuvalent is being referred to more favorably in the media.
Nuvalent presently has a consensus target price of $112.36, indicating a potential upside of 44.19%. Given Nuvalent's stronger consensus rating and higher possible upside, analysts plainly believe Nuvalent is more favorable than Beigene.
97.3% of Nuvalent shares are owned by institutional investors. Comparatively, 48.6% of Beigene shares are owned by institutional investors. 12.5% of Nuvalent shares are owned by company insiders. Comparatively, 7.4% of Beigene shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Nuvalent has a net margin of 0.00% compared to Beigene's net margin of -25.94%. Beigene's return on equity of -25.12% beat Nuvalent's return on equity.
Nuvalent received 43 more outperform votes than Beigene when rated by MarketBeat users.
Nuvalent has a beta of 1.38, suggesting that its share price is 38% more volatile than the S&P 500. Comparatively, Beigene has a beta of 0.63, suggesting that its share price is 37% less volatile than the S&P 500.
Summary
Nuvalent beats Beigene on 13 of the 16 factors compared between the two stocks.
Get Nuvalent News Delivered to You Automatically
Sign up to receive the latest news and ratings for NUVL and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Nuvalent Competitors List
Related Companies and Tools
This page (NASDAQ:NUVL) was last updated on 2/18/2025 by MarketBeat.com Staff